dalteparin and Complications of Diabetes Mellitus
dalteparin has been researched along with Complications of Diabetes Mellitus in 7 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"In the ACUITY trial, 13,819 patients with moderate- or high-risk acute coronary syndromes (ACS) were randomized to heparin (unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibition (GPI), bivalirudin plus GPI, or bivalirudin monotherapy." | 9.13 | Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. ( Attubato, MJ; Ebrahimi, R; Feit, F; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Stone, GW, 2008) |
"In the ACUITY trial, 13,819 patients with moderate- or high-risk acute coronary syndromes (ACS) were randomized to heparin (unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibition (GPI), bivalirudin plus GPI, or bivalirudin monotherapy." | 5.13 | Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. ( Attubato, MJ; Ebrahimi, R; Feit, F; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Stone, GW, 2008) |
"Diabetes mellitus is a major contributor to CAD." | 2.71 | Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. ( Diderholm, E; Lagerqvist, B; Lindahl, B; Malmberg, K; Norhammar, A; Rydén, L; Wallentin, L, 2004) |
" Recently, the use of safe-dose recombinant tissue-type plasminogen activator (rTPA) has been proposed for the treatment of moderate PE demonstrating to be safe and more effective than standard anticoagulation." | 2.50 | [Safe dose rTPA for massive pulmonary embolism associated with high bleeding risk: a case report and review of the literature]. ( Cannone, M; La Torre, PP; Mele, A; Mele, M, 2014) |
Research
Studies (7)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (57.14) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Ng, QX | 1 |
Seng, C | 1 |
Ho, CYX | 1 |
Yeo, WS | 1 |
Mele, M | 1 |
Mele, A | 1 |
La Torre, PP | 1 |
Cannone, M | 1 |
Carballo, S | 1 |
Carballo, D | 1 |
Keller, PF | 1 |
Roffi, M | 1 |
Morrow, DA | 1 |
Antman, EM | 1 |
Murphy, SA | 1 |
Qin, J | 1 |
Ruda, M | 1 |
Guneri, S | 1 |
Jacob, AJ | 1 |
Budaj, A | 1 |
Braunwald, E | 1 |
Feit, F | 1 |
Manoukian, SV | 1 |
Ebrahimi, R | 1 |
Pollack, CV | 1 |
Ohman, EM | 1 |
Attubato, MJ | 1 |
Mehran, R | 1 |
Stone, GW | 1 |
Skeppholm, M | 1 |
Kallner, A | 1 |
Kalani, M | 1 |
Jörneskog, G | 1 |
Blombäck, M | 1 |
Wallén, HN | 1 |
Norhammar, A | 1 |
Malmberg, K | 1 |
Diderholm, E | 1 |
Lagerqvist, B | 1 |
Lindahl, B | 1 |
Rydén, L | 1 |
Wallentin, L | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Prevalence of the Appearance of Diabetic Ulcers, After the Manufacture and Adaptation of Personalized Insoles, With Monitoring of Temperature and Plantar Pressure in Diabetic Patients[NCT05843929] | 86 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Reviews
1 review available for dalteparin and Complications of Diabetes Mellitus
Article | Year |
---|---|
[Safe dose rTPA for massive pulmonary embolism associated with high bleeding risk: a case report and review of the literature].
Topics: Aged, 80 and over; Anemia, Hypochromic; Anticoagulants; Bundle-Branch Block; Diabetes Complications; | 2014 |
Trials
3 trials available for dalteparin and Complications of Diabetes Mellitus
Other Studies
3 other studies available for dalteparin and Complications of Diabetes Mellitus
Article | Year |
---|---|
Enoxaparin: A cause of postoperative fever?
Topics: Aged; Animals; Anticoagulants; Arthroplasty, Replacement, Knee; Cattle; Diabetes Complications; Enox | 2018 |
[Specificities of diabetes in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Clopidogr | 2011 |
ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitus.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Case-C | 2009 |